Hypertension and myocardial ischemia.
Detailed studies over the past 30 years have built up an impressive evidence base for the presence of myocardial ischemia in patients who have hypertension. This relationship ranges from the obvious association with obstructive coronary artery disease to mechanisms related to hemodynamic, microcirculatory, and neuroendocrine abnormalities. All of these factors serve to destabilize the critical balance between myocardial oxygen supply and demand. We have at our disposal a range of sophisticated investigations that allow us to demonstrate the presence and extent of the ischemia and therefore to target specific therapies to reduce the risk to these patients. Achieving target BP and managing all reversible components of the patient's cardiovascular risk status reduce to a minimum the clinical sequelae of myocardial ischemia in this vulnerable population..
Cardiac Department, Stobhill Hospital, Glasgow, Scotland, UK.
Brian P
BP
Murphy
Tony
T
Stanton
Francis G
FG
Dunn
D000959:Antihypertensive Agents / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000209:etiology; D004727:Endothelium / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D009206:Myocardium / Q000473:pathology; D009490:Neurosecretory Systems; D018384:Oxidative Stress; D010477:Perfusion; D012307:Risk Factors
D000959:Antihypertensive Agents